Synera Venipuncture Pain

Completed · Phase 2 · Has a placebo group

Conditions studied: Pain, Phlebotomy, Palliative Care

In brief

Synera, which is a heated topical patch containing both lidocaine and tetracaine, is intended to reduce the pain associated with venipuncture and superficial dermatologic procedures by numbing the skin. This study will test the effectiveness of the Synera lidocaine/tetracaine patch when administered for 30 ± 5 minutes to provide dermal anesthesia in adult oncology patients undergoing venipuncture as part of their care, for treatment or diagnostics (laboratory or imaging). Compared to the use of the placebo patch, this study hypothesizes that the difference of 1 cm on the 0-10 visual analogue scale (VAS) will be observed 30 minutes after the use of the Synera patch. Pain intensity will be assessed by a 0-10 VAS

Key facts

Study ID

NCT01744197

Run by

US Oncology Research

People needed

61

Starts

2013-01-01

Expected to finish

2013-11-01

Last updated by the study team

2018-10-25

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with any tumor type where treatment is received through venipuncture or any procedure that is needle based or who require regular pharmacokinetic (PK) study.
• Is 18 years of age or older.
• Patients expected to undergo the first venipuncture procedure within 5 working days of enrollment.
• Male or female patients
• Has signed the most recent Patient Informed Consent Form
• Has signed a Patient Authorization Form (HIPPA)

You may not qualify if…

• Patients with sensitivity to lidocaine, tetracaine, or any other component of the product
• Known sensitivity to any components of test materials (sulphites and adhesives)
• Patients with damaged or broken skin at the designated patch site
• Pregnant or breastfeeding women patients
• Use of any immediate-release single-agent opioid product (ie, morphine, oxycodone, hydrocodone, hydromorphone, oxymorphone, or tramadol) or combination products containing acetaminophen or ibuprofen with one of these agents within 4 hours of the patient's visit
• Previous irradiation to the site of the patch

Where it is running

• 19 Locations Including — Dallas, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.